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ABSTRACT
The ongoing problem of emerging antimicrobial resistance has been likened to a balloon where settling
one speciﬁc issue results in a ‘bulge’ of even worse problems. However, much has been learned about
how to best use our critical antibacterial agents in ways to avoid or even repair some of the resistance
damage that has been done. A compilation of current literature strongly suggests that to slow the
development of resistance to antimicrobial agents it is optimal to use drugs with more than one
mechanism of action or target, to prescribe those with demonstrated ability to minimise or reverse
resistance problems, and to avoid underdosing of potent antibiotics. The most recent information also
indicates that it is best to limit empirical use of b-lactam plus ﬂuoroquinolone combination therapy,
since these two classes activate some common resistance responses, and using them together can
facilitate multidrug resistance in important pathogens, particularly Pseudomonas aeruginosa and
Acinetobacter species. This review discusses the role of each major antimicrobial class on resistance
development and presents speciﬁc strategies for combating the growing problem of multidrug-resistant
bacteria. We now have the knowledge to better manage our antimicrobial agent prescribing practices,
but ﬁnding the will and resources to apply our understanding remains a formidable challenge.
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INTRODUCTION
The beginning of the 21st century has been
accompanied by what appears to be an increasing
number of emerging infectious diseases, some
truly new, e.g., severe acute respiratory syndrome
(SARS) [1], and others caused by old microbes
possessing new resistance phenotypes (multi-
drug-resistant Pseudomonas aeruginosa and Acine-
tobacter spp.) or toxin (community-acquired
methicillin-resistant Staphylococcus aureus with
the Panton–Valentine leukocidin toxin) genes [2–
4]. It is as if we have passed through three distinct
eras over the last 100 years—moving from the
pre-antibiotic era through the antibiotic era and
into the era of emerging infectious diseases. Many
questions are worthy of consideration as we try to
understand why this is occurring, so as to better
cope with infectious diseases on both the personal
and global fronts. With very few new antimicro-
bial agents being introduced, and even fewer at the
discovery stage, a critical question to ask ourselves
is whether prescribing practice(s) can be improved
to reverse, or at least retard, that portion of the
emerging infections problem that is self-inﬂicted
by suboptimal use of our available antimicrobial
agents. The purpose of this review is to make a
critical assessment of what can be gleaned from
current evidence and suggest what might be
practically done to slow the process of bacteria
developing multidrug resistance. More than
10 years ago, Dr Harold Neu sounded the alarm
over increasing antibiotic resistance [5]. In a recent
report on the progress of pathogens, McGeer
correctly points out that antibiotic pressure pro-
vides a crucial facilitative role in the dissemination
as well as the development of resistance [6]. Thus,
an important focus for better use of antimicrobial
agents must be to assess the impact of major
antibacterial classes on development of resistance
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to their related compounds, as well as to explore
the impact that one class of antimicrobial agents
may have on enhancing resistance to unrelated
drugs.
THE IMPACT OF RESISTANCE TO
ANTIMICROBIAL AGENTS
This is a much-discussed and written-about topic,
and the great majority of evidence indicates the
importance of this healthcare issue. At the very
least, published data clearly suggest that when
people are admitted to the hospital with an
antibiotic-resistant bacterial infection, they are
much less likely to receive the proper initial
therapy, and this is associated with a costlier
hospital stay [7]. Considerable evidence also
conﬁrms that mortality rates are higher in patients
not given early therapy active against their infect-
ing microbe [8,9]. Some even consider the prob-
lem as a threat to our entire healthcare system
[10].
THE ORIGINS OF RESISTANCE TO
ANTIMICROBIAL AGENTS
It is not surprising that bacteria can readily adapt
to antibiotic exposure, since they have been in
existence, and thriving, for at least 3.8 billion
years [11]. An excellent schematic presentation of
the emergence and spread of resistance can be
found on the Dutch Working Party on Antibiotic
Policy web-site [12]. Resistance clearly begins
with antibiotic exposure, and even if only one or
two bacterial cells survive they have the oppor-
tunity to develop into resistant strains. Subse-
quently, these newly resistant microbes can pass
from person to person, amplifying to potentially
epidemic proportions. The dissemination is faci-
litated by imperfect infection control practices
and antimicrobial use in large numbers of people
that permits resistant pathogen spread among
persons with diminished protective normal ﬂora.
Thus, improving our use of antimicrobial agents
provides at least two opportunities to better
manage the emergence and spread of resistance.
The ﬁrst opportunity for improvement is to select
drugs and dosing regimens that minimise the
microbes’ ability to survive and thus prevent the
initial development of resistance. The second
opportunity is to use agents that limit the spread
of healthcare-associated infectious diseases and
microbial resistance, preventing what has come to
be referred to as collateral damage. Considerable
data are available on both aspects to facilitate the
wise choice and use of antimicrobial chemo-
therapy.
OPTIONS THAT CAN IMPROVE THE
USE OF ANTIMICROBIAL AGENTS
Throughout the last few decades of antibiotic use,
many ideas have arisen that can help practitioners
to better prescribe these agents. These include the
development of practice guidelines to improve
treatment uniformity, controls or restrictions on
what can be used based on expert decision-
makers and economic factors, professional edu-
cation, national guidelines by reputable policy-
makers, and recommendations for prudent use
through practices such as antibiotic step-down
prescribing and cycling [10]. However, to date,
none has had a noticeable impact on the problem
at hand. For the future, improved diagnostics and
information systems offer promise [13,14], but
these are still some years away. During the last
decade, much information has appeared in the
medical literature regarding the impact of speciﬁc
drugs and ⁄ or classes on the emergence, dissem-
ination and, occasionally, reversal of problems
relating to antibiotic resistance and the spread of
healthcare-associated pathogens. Using this infor-
mation can help us to enhance effective prescri-
bing and limit the ongoing development and
spread of microbial resistance. Additionally,
through the ﬁeld of pharmacodynamics, we have
learned much on how the actual administration of
antimicrobial agents can be either beneﬁcial or
detrimental, and this knowledge can be applied
today.
LESSONS FROM NATIONAL
SURVEILLANCE PROGRAMMES
In the late 1990s, Austin et al. published an article
that modelled the rise of antibiotic resistance and
the scope of remedies needed to reverse the
problem, with validation based on observations in
Finland and Iceland [15]. Their core ﬁnding was
that for each drug or drug class there is a level of
use that, once exceeded, will eventually lead to
resistance. Once this occurs, dramatic reductions
in drug prescribing are needed to reverse the
trend towards increasing resistance. In general, it
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appeared that once use exceeded 15–25 deﬁned
daily doses (DDD) per 1000 patients in a popu-
lation, resistance would typically occur at some
time-point. To reverse this, a major reduction in
use, as much as 50% or more, to achieve levels
below the antimicrobial agent’s resistance thresh-
old (generally no more than 25 DDD ⁄ 1000 pa-
tients) would be needed. For hospital settings, the
usual denominator used is 1000 patient-days. If
one assumes that the typical course of antibiotic
therapy is 10 days, then 25 DDD ⁄ 1000 patient-
days can be converted to 2.5% of patients receiv-
ing a given drug (or drug class) in the hospital or
nursing unit at any given time—an exceedingly
small amount in today’s healthcare environment.
Reviewing recent reports on national anti-
microbial consumption and accompanying resist-
ance problems is an instructive ﬁrst step for
understanding current resistance trends. In 2003,
Neuhauser et al. reported a large investigation
that recorded changes in bacterial susceptibility in
intensive care units (ICUs) across the USA [16].
Between 1994 and 2000, they recorded suscepti-
bility results for nearly 36 000 Gram-negative
bacilli along with the consumption of ﬂuoroqui-
nolones in the geographical area surrounding the
participating hospitals. The administration of
ﬂuoroquinolones increased by 147% and the
observed increases in resistance to various agents
were: 10% to quinolones, 6% to gentamicin, 3%
to ceftazidime and ampicillin–sulbactam, 2% to
cefotaxime, ceftriaxone and ticarcillin–clavula-
nate, 1% to imipenem, and 0% to piperacillin–
tazobactam. This would suggest that a threshold
had been reached for ﬂuoroquinolone use, and
the over-prescribing of this class was increasing
resistance in many Gram-negative bacteria to all
the ﬂuoroquinolone agents.
Information regarding antibiotic use and
bacterial resistance in The Netherlands is also
enlightening [12]. Between 1997 and 2001, the use
of amoxicillin–clavulanate rose from 143 to
169 DDD ⁄ 1000 patient-days, which represents a
very high level of use based on Austin’s calcula-
tions [12,15]. Fluoroquinolone use also increased,
from 40 to 49 DDD ⁄ 1000 patient-days. Interest-
ingly, signiﬁcant increases in resistance were only
seen for ﬂuoroquinolones in Klebsiella pneumoniae,
P. aeruginosa, Escherichia coli and S. aureus, and for
macrolides in S. aureus and Streptococcus pneumo-
niae [12]. The authors noted that in the preceding
5 years the use of macrolides and ﬂuoroquino-
lones in The Netherlands’s hospitals had doubled.
These data suggest that the threshold for increas-
ing ﬂuoroquinolone and macrolide resistance had
been surpassed here as well. Also of note, from
the aspect of minimising multidrug resistance
development, is the observation that the amount
of extended-spectrum cephalosporin non-suscep-
tibility for E. coli in The Netherlands remained at
less than 2% during 2003 [17], one of the lowest
levels in all of Europe. This raises the possibility
that use of b-lactamase-stabilised antibiotics such
as amoxycillin–clavulanate, the most commonly
used injectable agent in The Netherlands’ hospi-
tals, may not be as prone to facilitate the
emergence and ⁄ or spread of resistance as com-
pounds in the ﬂuoroquinolone and macrolide
classes.
A third study, from the UK, assessed any
changes in piperacillin–tazobactam activity 9
years after this drug was introduced. There was
no change in activity against P. aeruginosa (95%
susceptible) or Proteus spp. during the 9 years, but
some problems were detected: resistance rose in
E. coli from 4% to 10%, in Klebsiella spp. from 5%
to 21%, and in AmpC-inducible Enterobacteria-
ceae from 17% to 23% [18]. However, no infor-
mation concerning drug use was provided, so it is
difﬁcult to assess what agent(s) may have been
responsible for these changes.
As a ﬁnal example, national antimicrobial
agent (injectable) usage data are available for
Malaysia. During 2002, some 62% of admin-
istered antibiotics were extended-spectrum
cephalosporins, another 13% were of the
carbapenem class and 7% were ﬂuoroquinolo-
nes (data obtained from the IMS Retail and
Provider Perspective. Plymouth Meeting, PA,
USA). The major problem reported for ICU
patients is infection with cephalosporin-resistant
Acinetobacter spp., representing nearly 50% of
isolates. Nearly 33% of Klebsiella spp. strains
and 8% of E. coli are also resistant to extended-
spectrum cephalosporins [19]. Importantly, of
the total injectable antibiotic given, 17% was
cefoperazone–sulbactam, which is recommended
for use at a very low dosage of 1–2 g every 12 h
[20,21]. A lead article written 20 years earlier
demonstrated that for cefoperazone to be ade-
quately dosed to achieve the standard suscep-
tibility breakpoint of 16 g ⁄L the administered
active drug must be given at a dose of between
2 and 3 g every 6 h [22]. This information
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suggests that predominant use of broad-spec-
trum cephalosporins, particularly when potent
entities are given at very low doses, has a
strong potential to facilitate the emergence of
many bacterial strains resistant to this entire
class of antimicrobial agents.
There is considerable variation in the use of
antimicrobial agents across the world and even
within geographical areas with close social and
economic ties, such as the European Union [23].
In order to start devising a plan for altering
prescribing practices, one ﬁrst needs to know
what problems are being faced locally, as only
then can a rational plan for improvement be
developed, and the necessary implementation on
the part of prescribing physicians be achieved.
What follows is the evidence from the recent
literature as to what agents and classes of drugs
contribute to the emergence and spread of resist-
ance, accompanied by examples of what has
worked in clinical practice to stabilise or reverse
the problem. Basic science is also adding to our
understanding of why certain chemical com-
pounds may be more problematic, and this will
be commented upon whenever appropriate.
IMPACT OF USING SPECIFIC
CLASSES OF ANTIMICROBIAL
AGENTS
There are a limited number of antimicrobial drug
classes used for treatment of infectious diseases
within the hospital setting. These include amino-
glycosides, carbapenems, cephalosporins, ﬂuoro-
quinolones, penicillins, and vancomycin, and
there is also growing application of the new
compounds linezolid and quinupristin–dalfopris-
tin, which are reserved for speciﬁc, limited indi-
cations. It is instructive to review the applicable
experience concerning the impact of using each of
the therapeutic classes.
Aminoglycosides
Aminoglycosides have been available since the
early onset of the antibiotic era, with streptomycin
reported in 1944 [24]. Resistance is mediated by
several mechanisms, ranging from efﬂux to
impaired uptake to target modiﬁcation and enzy-
mic inactivation [24]. However, there is little
evidence that the aminoglycosides mediate resist-
ance to other drug classes. Even when impacted
by resistance themselves, these drugs are well-
known for their capacity to exhibit synergistic
activity with cell wall-active agents [24].
In 1991, Gerding et al. reported their experience
with rotation, or cycling, of gentamicin and
amikacin to manage the problem of emerging
resistance in Enterobacteriaceae against gentami-
cin. In each of the cycles, they were able to switch
use of gentamicin from between 50 and
100 DDD ⁄ 1000 patient-days to fewer than 5, a
ten-fold decrease, and over amikacin cycle peri-
ods of 2 years they saw the desired change of
increased susceptibility to gentamicin [25]. From
what they report, the only observed effect was on
the aminoglycoside susceptibility of the hospital’s
bacteria. Similar results were obtained from a
comparable study done in Belgium [26]. A large,
additional evaluation of aminoglycoside prescri-
bing in 14 US hospitals also provided ﬁndings
consistent with those of Gerding et al., with a
switch to amikacin providing improved amino-
glycoside activity against Gram-negative patho-
gens, including P. aeruginosa, Klebsiella, Serratia,
and Proteus spp. [27]. This experience indicates
little impact of the aminoglycosides on the sus-
ceptibility of bacteria to other agents, but a clear
effect of drug consumption and resistance within
their own class of antibiotics. It also shows that for
the problem of signiﬁcant resistance to gentami-
cin or tobramycin, changing (cycling) to amikacin
for up to 2 years can re-establish susceptibility to
the aminoglycosides.
Carbapenems
Imipenem and meropenem are considered by
most to be the two agents with the widest
antibacterial spectrum of any available antibiotic
class, due to their considerable b-lactamase sta-
bility [28]. Early on it was recognised that per-
meability-mediated resistance was important for
the carbapenem class, particularly for organisms
such as P. aeruginosa and Acinetobacter spp. [28].
Zinc-dependent carbapenemases are potent inac-
tivating enzymes mediating resistance to the
carbapenems, but to date have remained of
limited importance, because of their presence in
only a few bacterial species [28].
Despite the very broad spectrum of activity of
this antibiotic class, the initial publication associ-
ating a ‘balloon concept’ with antibiotic resistance
arose from a study in which imipenem was
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substituted for cephalosporins in order to reduce
the rate of occurrence of cephalosporin-resistant
K. pneumoniae [14,29]. Rahal et al. were able to
reduce ceftazidime use by 73% and cefotetan use
by more than 95%, but this was accompanied by a
140% increase in imipenem prescribing. While
the authors’ efforts succeeded in reducing the
occurrence of cephalosporin-resistant Klebsiella
spp. by 44%, they observed a 69% increase in
imipenem-resistant P. aeruginosa within their
medical centre [29]. Burke argued that the
improvement in activity against Klebsiella spp.
may have pushed the antibiotic balloon and
resulted in an outcome with more resistance in
P. aeruginosa, giving an overall result less helpful
than desired [14].
The major current problem in the use of the
carbapenem antibiotics constitutes highly resist-
ant Gram-negative pathogens represented by
P. aeruginosa and Acinetobacter spp., both of which
encompass multiple modes for developing resist-
ance [2]. The most important mechanism is
probably that of upregulated efﬂux, particularly
when associated with loss of outer-membrane
(permeability) proteins such as the porin OprD.
Complicating resistance to this class is the fact
that OprD is co-regulated by the efﬂux system
MexEF–OprN, which can be selected by ﬂuoro-
quinolones [2]. When such a selection is generated
by a ﬂuoroquinolone, even without exposure to a
carbapenem, the strain of P. aeruginosa will be
resistant to the ﬂuoroquinolones and imipenem,
and also have reduced susceptibility or resistance
to meropenem. The increasing number of
acquired carbapenemases being found in P. aeru-
ginosa and Acinetobacter spp. will only add to the
growing carbapenem resistance problem [30].
When Acinetobacter baumannii becomes resident
in a healthcare setting, an important risk factor for
acquisition of a carbapenem-resistant strain is
treatment with one of these agents [31,32]. Also,
once carbapenem-resistant Acinetobacter spp. are
present in a region, thesebacteria have apropensity
to spread throughout the geographical area [33].
Overall, the data support the conclusion that
carbapenems are susceptible to fairly rapid resist-
ance development and lead to the spread of
carbapenem-resistant strains of P. aeruginosa and
A. baumannii when frequently used in the clinical
setting. With high-level use, resistance can also
occur in other genera, such as Citrobacter spp. [34].
As will be discussed in detail later, there is also
the strong implication that ﬂuoroquinolones
select for joint quinolone–carbapenem resistance
in these microbial genera, thus contributing to the
problem of carbapenem and multidrug resistance
in both P. aeruginosa and Acinetobacter spp. The
recent data from the National Nosocomial Infec-
tions Surveillance (NNIS) system highlight the
problem of increasing carbapenem resistance in
P. aeruginosa [35]. The pooled mean carbapenem
use in non-ICU inpatient areas between January
1998 and June 2003 was 5.9 (ranging from 0.4 to
14.8) DDD ⁄ 1000 patient-days, while in these same
care areas the mean ﬂuoroquinolone use was 68.3
(ranging from 24.8 to 177.0) DDD ⁄ 1000 patient-
days. Despite the fact that the use of carbapenems
was well below that expected to engender the
emergence of resistance, 12.4% (range 5.2–20.6%)
of P. aeruginosa strains were resistant to imipe-
nem. Not surprisingly, an average of 27.2 ⁄ 29.4%
(range 12.9 ⁄ 14.2% to 42.9 ⁄ 44.7%) of these same
isolates were also resistant to ciproﬂoxacin–levo-
ﬂoxacin [35]. This information strongly reinforces
the concept that carbapenem resistance in
microbes such as Acinetobacter spp. and P. aerugi-
nosa is most likely caused by overuse of ﬂuoro-
quinolones, which upregulate efﬂux systems that
export both quinolones and carbapenems [36].
Extended-spectrum cephalosporins
The extended-spectrum cephalosporins have come
to be used in a wide variety of clinical settings. The
currently available agents penetrate cerebrospinal
ﬂuid and have signiﬁcant advantages over past
treatments for bacterial meningitis. They are con-
sidered to have good clinical efﬁcacy as well as a
low rate of side-effects, and thus have become the
agents of choice for many infectious diseases [37].
The bacterial responses to exposure to agents that
are active against the key synthetic pathways for
cell wall synthesis are multifaceted. Bacteria, par-
ticularly Gram-negative bacilli, produce both chro-
mosomal and plasmid-mediated resistance
enzymes (b-lactamases) that are continually grow-
ing in number and phenotypic expression
[30,38,39]. For bacteria such as P. aeruginosa and
Acinetobacter spp., limiting drug penetration
through shedding of porins and upregulating
efﬂux pumps is complementary to b-lactamase
production and leads effectively to high levels of
resistance, much as is seen for the carbapenems. It
is likely that this combined mechanism is
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important for most Gram-negative bacteria to a
lesser or greater extent. Acinetobacter spp. are also
naturally competent and can remodel their target
sites as an added resistance mechanism [30,38,39].
In US hospitals, the extended-spectrum
cephalosporins appear to be the most frequently
prescribed antimicrobial agents, with an average
of 93.7 DDD ⁄ 1000 patient-days used in non-ICU
areas, and mean use in the ICU setting ranging
from 122.4 to 327.9 DDD ⁄ 1000 patient-days. With
this extremely high level of use, it is not surpris-
ing that in the ICU setting resistance to
P. aeruginosa and Enterobacter spp. has reached
13.8% and 26.6%, respectively [35]. Even with
inconsistent screening for extended-spectrum
b-lactamase (ESBL) production, resistance in
K. pneumonia now exceeds 5% [35]. The directly
related consequences of excessive use of these
agents are indicated by growing problems with
ESBL-producing Enterobacteriaceae [40] and
A. baumannii resistant to multiple antibiotic
classes [32,41]. Unfortunately, use of extended-
spectrum cephalosporins has also become associ-
ated with ‘collateral damage’ by facilitating
infections due to methicillin-resistant S. aureus
(MRSA) [42] and vancomycin-resistant enterococ-
ci (VRE), with one association linked to ticarcillin–
clavulanate, which behaves in this setting like a
cephalosporin with no activity against enterococci
[43–45]. The persistent problem of Clostridium
difﬁcile-associated diarrhoea (CDAD) is also rela-
ted to cephalosporin prescribing [46–48], with
beneﬁt from lowering cephalosporin use having
been demonstrated [49].
Extended-spectrum penicillins
The penicillins that have received the most
attention in recent research trials are those
comprising the group of combination agents
where part of the antibiotic includes a b-lacta-
mase inhibitor drug such as clavulanate, sulbac-
tam or tazobactam. In addition to being potent
inhibitors of Ambler class A (plasmid-mediated)
b-lactamases [30,38,39], they have been shown to
contribute additional effects by binding to acces-
sory penicillin-binding proteins, the key targets
of penicillin compounds. These additional pro-
perties include enhanced killing of MRSA
(compared to vancomycin) in an in-vivo animal
model [50], better in-vitro bactericidal activity
against Gram-negative and Gram-positive
bacteria [51] and augmented intracellular killing
of non-b-lactamase-producing bacteria by
neutrophil leukocytes [52]. With this evidence
for the multifactorial action of b-lactam ⁄b-lacta-
mase inhibitor compounds in mind, it is not
surprising that they are becoming recognised as
very important agents in the battle against
emerging resistance.
Clinical use of these agents presents the best
evidence for their role in combating bacterial
resistance. As noted earlier, use in The Nether-
lands has been high, but has not been accompan-
ied by increasing resistance development [12].
However, most importantly, many investigators
have demonstrated the utility of using these
compounds to reverse problems with ESBLs,
VRE and CDAD. While not extensively studied,
use of these agents may even help to better
manage the increasing prevalence of MRSA [53],
as evidenced by the fact that the ﬁrst patient
infected with vancomycin-insensitive MRSA was
actually cured by administration of ampicillin–
sulbactam [54].
The most extensive published clinical experi-
ence concerns the substitution of one of these
agents for an extended-spectrum cephalosporin to
reduce the prevalence of ESBL-producing bacteria
[53,55–61]. Two of these studies are particularly
worth highlighting. The ﬁrst, by Pen˜a et al.,
replaced third-generation cephalosporins with
imipenem–cilastatin and piperacillin–tazobactam,
and showed that once they were able to maintain
cephalosporin use below 25 DDD ⁄ 1000 patient-
days, the rate of ESBL-producing bacteria fell
from 40% to 0% [56]. The second study, by Bantar
et al., used piperacillin–tazobactam to replace
third-generation cephalosporins as an interven-
tion to reduce the high level of ESBL-producing
K. pneumoniae, in a setting where a prior switch to
cefepime had failed to provide the desired effect
[61]. They lowered ceftazidime and ceftriaxone
use from 17.8 to 1.1 DDD ⁄ 1000 patient-days and
12.7–5.7 DDD ⁄ 1000 patient-days, respectively,
whereas the overall prescribing of piperacillin–
tazobactam rose from 0 to 30.6 DDD ⁄ 1000
patient-days. The rate of ESBL-producing
K. pneumonia dropped from 68% to 37%, and
interestingly, the resistance in P. aeruginosa
against piperacillin–tazobactam also fell, from
11% to 6%, despite heavy use of that agent [61].
The impact of using b-lactamase inhibitor
compounds has also been investigated in the
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management of VRE, in a study that is the only
published investigation of antibiotic cycling deal-
ing with Gram-positive pathogens [62]. In this
most interesting intervention, Bradley et al. re-
placed ceftazidime with piperacillin–tazobactam,
and then cycled back to ceftazidime use. They
also accompanied their antibiotic intervention
with an enhanced infection control programme.
By implementing both an expanded infection
control programme and replacing extended cep-
halosporin use with a b-lactamase inhibitor drug,
they reduced the rate of colonisation with VRE
from 57% to 8%, and in doing so completely
eliminated all clinical infections. However, upon
the switch back to ceftazidime, the rate of colo-
nisation with VRE rose to 36% and clinical
infections reappeared in patients cared for on
the nursing unit [62]. It is also noteworthy that the
increase in colonisation with VRE and the return
of clinical infections with this multidrug-resistant
pathogen only took 4 months after the switch
back to ceftazidime, implying that a cycling
strategy to minimise problems with this microbe
is not useful. Supporting this prospective trial are
observational studies such as that by Donskey
et al., who demonstrated a protective effect
against acquisition of VRE with receipt of amp-
icillin–sulbactam or piperacillin–tazobactam vs.
an increased risk of infection with administration
of cephalosporins and ticarcillin–clavulanate [44].
Results similar to those of Bradley et al. were
reported in the more recent article by Kolar et al.
[63].
The ﬁnal context in which a prospective
clinical trial demonstrates the utility of b-lacta-
mase inhibitor compounds in managing health-
care-associated infectious diseases is that of
CDAD. Settle et al. performed a well-designed
crossover study comparing the impact of cefo-
taxime and piperacillin–tazobactam use on the
prevalence of this very important healthcare
pathogen [64]. They demonstrated a statistically
signiﬁcant reduction in both colonisation and
infection for the piperacillin–tazobactam arm of
the study, with rates of colonisation nearly four-
fold lower with piperacillin–tazobactam, and
those of infection reduced by nearly ten-fold,
compared to cefotaxime [64]. Importantly, this
trial is supported by a large retrospective obser-
vational investigation demonstrating the low
association of ticarcillin–clavulanate with the
development of CDAD (0 cases in nearly 62 000
doses administered) as compared to extended-
spectrum cephalosporins (51 cases for some
40 000 doses given), thus demonstrating the risk
associated with receiving a cephalosporin vs. a b-
lactamase inhibitor combined compound [65].
The results of Settle et al. are further reinforced
by the experience of Wilcox et al., who changed
from cefotaxime to piperacillin–tazobactam use,
and then back to cefotaxime when the inhibitor
combination became temporarily unavailable
[66]. During the initial switch when cefotaxime
use was curtailed, CDAD rates fell by over 50%,
and with the re-introduction of cefotaxime they
rose by 232% [66], once again supporting the
replacement of cephalosporin prescribing with
piperacillin–tazobactam as an effective strategy to
reduce the overall burden of CDAD.
Fluoroquinolones
Fluoroquinolones are some of the most important
antimicrobial agents that we have for treatment of
serious infections. They act directly on the
bacterial chromosome with lethal effect on micro-
bial replication processes [67,68]. Unfortunately,
their overuse is now associated with a myriad of
emerging resistance consequences, some directly
affecting the ﬂuoroquinolone class [16], and
others impacting on resistance and emerging
infections in unanticipated ways. One of
the recently recognised critical mechanisms
of resistance is that resulting from induction of
efﬂux-pump activity. It is now known that ﬂuor-
oquinolones can select for mutants of Gram-
negative bacteria that overproduce a wide variety
of efﬂux pumps and in a single step cause
resistance to practically all classes of antimicrobial
agents [9,69]. A growing concern is the problem
apparently caused by heavy use of these agents in
association with increasing resistance to other
agents, such as carbapenem resistance in
P. aeruginosa [70,71]. Since ﬂuoroquinolones can
turn on several multidrug-efﬂux systems that also
affect carbapenems [70,71], heavy use of these
agents in hospitals can facilitate the development
of multidrug-resistant P. aeruginosa and leave
little available therapy for treatment of these
infections. A recent matched case-control study
investigating the role of antimicrobial therapy in
acquisition of multidrug-resistant P. aeruginosa
supports the in-vitro science implicating prior
receipt of a ﬂuoroquinolone as the major
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independent risk factor for the emergence of these
pathogens [72]. This accumulating evidence indi-
cates that it is best to avoid the use of ﬂuoroqu-
inolones and b-lactams as a combination for
empirical therapy of serious infection. If one
begins treatment with a b-lactam plus an amino-
glycoside (when two agents are desirable) for the
ﬁrst 48–72 h, and either discontinues the amino-
glycoside if cultures are negative, or changes to
speciﬁc therapy once the organism identiﬁcation
and susceptibility are known, then a signiﬁcant
reduction in ﬂuoroquinolone use can be achieved,
with little risk of aminoglycoside nephrotoxicity
or the need for therapeutic drug monitoring
[73,74].
Fluoroquinolones, like other antimicrobial
agents, directly inﬂuence the level of resistance
to themselves in many bacterial species, as evi-
denced in large surveillance studies of the last few
years [16,75,76]. We demonstrated in 1998 that
introduction of a second agent in the quinolone
class to the hospital setting was accompanied by
increased prescribing and rapidly led to increas-
ing ﬂuoroquinolone resistance in P. aeruginosa
[77]. Importantly, with withdrawal of the less
active agent and lowering of overall use, it was
possible to achieve a reversal of the resistance
trend [77]. Supporting our ﬁnding is the recent
report by Paladino et al., who demonstrated that
treatment with a weaker-potency ﬂuoroquinolone
predisposed to later infection with quinolone-
resistant P. aeruginosa [78]. Some of the newer
ﬂuoroquinolone agents are less susceptible to
efﬂux than are the older compounds [79,80], and
it remains to be learned if preferential use of
agents such as moxiﬂoxacin, especially against
Gram-positive pathogens, can slow the future
development of resistance against this important
antimicrobial class.
One of the current major concerns arising from
the use of ﬂuoroquinolone antimicrobial agents
is the concept of ‘collateral damage’, or the
enhanced spread of drug-resistant pathogens that
at ﬁrst glance do not seem to be associated with
administration of the offending compound(s). In
addition to the concern that these agents can cause
resistance to b-lactams in Gram-negative bacteria,
there are recent reports linking the spread of
MRSA to ﬂuoroquinolone prescribing [81–83],
and an increased prevalence of CDAD linked to
use of levoﬂoxacin and gatiﬂoxacin [85–87].
Harbarth et al. found that prior receipt of a
ﬂuoroquinolone was an independent risk factor
for persistence of MRSA carriage and failure of
mupirocin decolonisation, even in the absence of
high-level mupirocin resistance [81]. Graffunder
and Venezia also reported that quinolone (levo-
ﬂoxacin) exposure was independently associated
with MRSA infection (odds ratio ¼ 8.01) in a large
case-control study of 121 patients [82]. Similar
ﬁndings were recently described by Weber et al.
[83]. These investigators even suggested a mech-
anism that can facilitate MRSA colonisation after
exposure to ﬂuoroquinolones. They recalled that
Bisognano et al. demonstrated that ciproﬂoxacin
exposure leads to increased expression of adher-
ence factors promoting host colonisation with
S. aureus [84]. Signiﬁcant changes in adhesion
were exhibited when strains were grown in the
presence of 1 ⁄ 4 MIC of the quinolone, a level of
exposure that would be expected in the case of
MRSA, since MRSA strains are now largely
resistant to all available ﬂuoroquinolones [83].
This concept could also explain the persistence of
colonisation noted earlier by Harbarth et al. [81].
CDAD has recently come to be associated with
ﬂuoroquinolone prescribing. McCusker et al.
found the greatest association with levoﬂoxacin
prescribing, while Gaynes et al. tracked an out-
break to a switch from levoﬂoxacin to gatiﬂoxacin
use [85,86]. In his editorial, Gerding implicated all
ﬂuoroquinolone (over)use as causing emerging
resistance in yet another microbial pathogen,
C. difﬁcile, this in turn leading to spread of this
organism among patients within the hospital
environment [87]. It is clear that high levels of
ﬂuoroquinolone use can lead to several different
adverse consequences, and that only through
careful surveillance to detect problems, and
thoughtful planning to deal with them, can
healthcare providers effectively manage these
consequences.
Vancomycin
Vancomycin is a naturally occurring antibiotic
that has been marketed for over 40 years [88]. The
agent is considered to be bactericidal to most
Gram-positive bacterial species, but to have no
activity against Gram-negative pathogens,
because of its bulkiness. The action of this
antimicrobial agent involves blocking synthetic
enzyme access to the acyl–D-ala–D-ala portion of
the peptidoglycan precursor, thus stopping
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completion of the cell wall structure [88]. The
main resistance to vancomycin is directly related
to its use, and was very slow to emerge; it
required nearly 30 years after the 1958 launch of
vancomycin for the ﬁrst vancomycin-resistant
enterococci to appear [89]. There does not appear
to be any impact on other antimicrobial classes
associated with the use of vancomycin.
New antimicrobial agents
The newest injectable antimicrobial classes are the
oxazolidinones, represented by linezolid [90], and
the streptogramins, of which quinupristin–dal-
fopristin is currently the only available member
[91]. These compounds are too new on the
therapeutic scene for any adverse resistance
implications resulting from their use or overuse
to have been determined. However, if history is to
be a teacher for us, we will need to remain
vigilant and watch for unexpected consequences
of the introduction of these welcome new com-
pounds.
THE ROLE OF APPROPRIATE
ANTIMICROBIAL AGENT DOSING IN
MINIMISING EMERGING
RESISTANCE
The primary goal of antibiotic treatment is to cure
the patient of infection, with avoiding resistance
being secondary (at best) in the mind of the
prescribing physician [92]. Over the last decade
we have learned much about the theoretical and
practical pharmacodynamic approaches to pre-
scribing that can help achieve this ﬁrst goal
[93,94]. For example, it is clear that the ratio of
peak drug concentration to the MIC for the
infecting pathogen maximises bacterial killing
for aminoglycosides, and therefore most dosing
is now done as a single daily administration
[95,96]. We also now understand that the ratio of
Table 1. Recommendations (with ratingsa) for management of antimicrobial agent resistance
Problem Useful solution Rating References
1. High levelb of carbapenem-resistant
P. aeruginosa
Reducec ﬂuoroquinolone and ⁄ or carbapenem
use
BIII [2,9,35,69–72]
2. High level of ﬂuoroquinolone-
resistant P. aeruginosa
Reduce ﬂuoroquinolone use and change
primary drug to ciproﬂoxacin
AI [9,16,67,69,75–78]
3. High level of carbapenem-resistant
A. baumannii
Reduce carbapenem use and assess for
clonal problem
AII [31–33]
4. High level of b-lactam resistance in
P. aeruginosa
Reduce extended-spectrum cephalosporin
use and replace with piperacillin–tazobactam
BIII [35]
5. High level of ESBL-producing
Enterobacteriaceae
Reduce extended-spectrum cephalosporin use
and replace with piperacillin–tazobactam or
imipenem–cilastatin or ampicillin–sulbactam
AI [29,53,55–61]
6. High level of gentamicin–tobramycin
resistance in Enterobacteriaceae
Replace with amikacin AI [25–27]
7. Concern over presence of VRE Reduce cephalosporin and ﬂuoroquinolone use
and replace with piperacillin–tazobactam
AI [43–45,62,63]
8. Concern over presence of MRSA Reduce cephalosporin and ﬂuoroquinolone
use, and replace with a b-lactamase
inhibitor drug
BIII [50,53,54,81–84]
9. Concern over presence of C. difﬁcile Reduce cephalosporin, clindamycin and
ﬂuoroquinolone use and replace with:
(a) piperacillin–tazobactam or
(b) ticarcillin–clavulanate
AI and BIII,
respectively,
for (a) or (b)
[49,64–66,85–87]
ESBL, extended-spectrum b-lactamase; VRE, vancomycin-resistant enterococci; MRSA, methicillin-resistant Staphylococcus
aureus.
aRatings follow the convention recommended by the Infectious Diseases Society of America for the evidence to support
each recommendation [99].
bHigh level indicates resistance exceeding 10% of recovered strains.
cA reduction is represented by a lowering of prescribing by at least 50% (based on deﬁned daily doses (DDD) ⁄ 1000 patient-
days) with a goal of using less than 15 DDD ⁄ 1000 patient-days of the likely offending agent. (Note: If use when the
problem is detected is below 15 DDD ⁄ 1000 patient-days, then the affected agent ⁄ class is not likely to be responsible for the
resistance problem.)
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the 24-h area under the serum concentration
curve (AUC) and the MIC is related to successful
therapy with ﬂuoroquinolones, macrolides, keto-
lides and glycopeptides; and that the time above
the MIC best predicts treatment success for
b-lactams, tetracycline and oxazolidinones. This
understanding must be applied not only to
patients, but also to our overall prescribing and
stewardship of these important drugs in the battle
against facilitating resistance. As an example,
when potent agents such as cefoperazone–sulbac-
tam are routinely prescribed at less than one-
quarter the required dose for Gram-negative
pathogens in areas such as Malaysia [20–22] and
India (author’s unpublished data), it is not sur-
prising that very high levels of multidrug-resist-
ant pathogens emerge [19,97,98], and this practice
should not be tolerated by physicians or encour-
aged by the pharmaceutical industry.
SUMMARY
Much useful information on how to limit, avoid
and even reverse resistance to antimicrobial
agents has become available over the last decade.
The bulk of the literature appears to suggest
several critical options. An important ﬁrst step is
to perform local surveillance so as to understand
what problems are being faced in one’s own
practice area. Once the problems are recognised,
there are now well-evidenced steps that can be
taken to slow, or even reverse, the development of
resistance. Table 1 lists the current most import-
ant resistance problems along with potential
solutions, each documented by ratings as to how
well the proposed intervention has been investi-
gated. The ratings follow the recommendations
developed by the Infectious Diseases Society of
America for such a guideline [99], and the ratings
used are explained in Table 2. In general, based
on this review, to slow the development of
resistance to antimicrobial agents, the current
literature strongly suggests that we use agents
with more than one mechanism of action or
target, use agents with demonstrated ability to
minimise resistance, avoid combining b-lactams
and ﬂuoroquinolones for empirical therapy
against Gram-negative pathogens, and avoid
underdosing of potent antibiotics.
In conclusion, we have now had some 50 years
of experience in prescribing antimicrobial com-
pounds and much insight has been gained, as
described above. At this point in our use of
antimicrobial drugs, McGeer’s quote from Goethe
seems most appropriate [6]:
Knowing is not enough; we must apply.
Willing is not enough; we must do.
The future of infectious disease management is
up to each of us!
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